Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 118.12B |
| Revenue (ttm) | 55.02B +4.3% |
| Net Income | 4.50B |
| EPS | 3.86 |
| Shares Out | n/a |
| PE Ratio | 26.28 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,459,644 |
| Average Volume | 1,619,079 |
| Open | 9,777.00 |
| Previous Close | 9,956.00 |
| Day's Range | 9,450.00 - 10,160.00 |
| 52-Week Range | 4,865.00 - 11,100.00 |
| Beta | 0.66 |
| RSI | 50.13 |
| Earnings Date | Jan 28, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, ...
Teva Pharmaceutical Industries Limited 2025 Q4 - Results - Earnings Call Presentation
2026-01-28. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2025 Q4 earnings call.
Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals
Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals
TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals
TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals
TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies
TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Teva Pharmaceutical Industries (TEVA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metri...
TEVA Aims to Double Biosimilar Revenue by 2027
TEVA Aims to Double Biosimilar Revenue by 2027
TEVA: Progress in Transformation Initiatives and Future Financial Expectations
TEVA: Progress in Transformation Initiatives and Future Financial Expectations
Teva Pharma Slides On Light 2026 Outlook Despite Fourth-Quarter Beat
Teva stock slipped early Wednesday on light 2026 guidance. The drugmaker, known for generics, easily beat fourth-quarter forecasts.
Teva Pharmaceutical (TEVA) Surpasses Q4 Expectations with Strong Earnings
Teva Pharmaceutical (TEVA) Surpasses Q4 Expectations with Strong Earnings
Teva Pharmaceutical (TEVA) Surpasses Q3 Earnings Expectations
Teva Pharmaceutical (TEVA) Surpasses Q3 Earnings Expectations
Teva (TEVA) Projects Lower 2026 Financials Despite Q4 2025 Beat
Teva (TEVA) Projects Lower 2026 Financials Despite Q4 2025 Beat
Earnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY26 outlook below forecast
Teva (TEVA) Reports Strong Q4 Revenue, Highlights Growth Strategy
Teva (TEVA) Reports Strong Q4 Revenue, Highlights Growth Strategy
Teva projects revenue drop in 2026 despite Q4 beat
Teva (TEVA) Reports Robust Growth and Strategic Advancements in 2025
Teva (TEVA) Reports Robust Growth and Strategic Advancements in 2025
TEVA Projects Revenue Growth with Promising Pipeline Developments
TEVA Projects Revenue Growth with Promising Pipeline Developments
Teva Pharmaceutical profit, revenue rise in fourth quarter
Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in fourth-quarter profit, boosted by sales of its branded drugs as well as a milestone payment to begin a late stage st...
Teva Pharmaceutical Turns To Profit In Q4, Announces FY26 Outlook
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributable to the compa...
Teva Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.32, revenue of $4.71B beats by $380M
Teva Pharmaceutical Industries Q4 25 Earnings Conference Call At 8:00 AM ET
(RTTNews) - Teva Pharmaceutical Industries (TEVA) will host a conference call at 8:00 AM ET on January 28, 2026, to discuss Q4 25 earnings results.
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Ja...
Earnings Scheduled For January 28, 2026
Companies Reporting Before The Bell • VF (NYSE: VFC) is estimated to report quarterly earnings at $0.43 per share on revenue of $2.76 billion. • Elevance Health (NYSE: ELV) is estimated to report qu...
Teva Pharmaceutical (TEVA) Q4 Earnings Preview: What to Expect
Teva Pharmaceutical (TEVA) Q4 Earnings Preview: What to Expect